[Comparative evaluation of the efficacy of using terazosin and tamsulosin in patients with benign prostatic hyperplasia].
OBJECTIVE
To evaluate effectiveness and safety of terazosin vs tamsulosin in patients with benign prostatic hyperplasia (BPH); to elucidate effectiveness of the use of tamsulosin followed by terazosin and vice versa.


METHODS
Group 1 of BPH patients received terazosin (5 mg/day) followed in a month by tamsulosin (0.4 mg/day). Group 2 received the same drug in the opposite sequence. The trial included 60 patients with symptoms of the lower urinary tracts due to BPH. The results were assessed on the treatment day 5-7, 14, 30 and 60 one month after the treatment termination.


RESULTS
Terazosin and tamsulosin relieved clinical symptoms, reduced QOL and Qmax. One month after the treatment the symptoms partially returned to baseline, Qmax returned completely. In cross-over, positive trends were weaker.


CONCLUSIONS
Clinical efficiency of both drugs was comparable, there was no cross effect. A month interval between the treatments in this case was insufficient. This should be taken into account when planning further studies.
Lopatkin
N A
NA
Sivkov
A V
AV
Surikov
V N
VN
Egorov
A A
AA
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; C041226:Terazosin; D000077409:Tamsulosin; D011224:Prazosin